Technologies

Our scientists have identified a coupling between two functionally distinct dopamine receptors (D1 and D2) as a novel target for treatment of depression. Through the characterization of the protein‐protein receptor interaction we have developed a small peptide that selectively interferes with this coupling, thereby leading to the development of a breakthrough therapy capable of delivering enhanced affinity, efficacy, and a superior side effect profile.